Warfarin or dabigatran for treatment of atrial fibrillation.
J Thromb Haemost. 2014 Apr 26;
Authors: Poller L, Jespersen J, Ibrahim S, The European Action on Anticoagulation (EAA)
New antithrombotic drugs for prevention and treatment of thrombo-embolic disorders in AF which are less demanding on local staff and facilities than warfarin should be welcomed if proved successful. The comparative value and possible dangers of substituting the new drug dabigatran as a replacement remain to be established. Its safety and effectiveness must be reviewed and assessed by further study. Evaluations should recognise optimum requirements for safe and effective administration of both types of drug. In the warfarin arm improvements in effectiveness and safety recently introduced i.e. the PT/INR Line and Variance Growth Analysis should be included as they have been shown to be successful in improved prediction of bleeding and further thrombo-embolism. The incidence of bleeding with dabigatran for which there is no antidote will require evaluation. This article is protected by copyright. All rights reserved.
PMID: 24766817 [PubMed - as supplied by publisher]